Niu et al. showed that a 12-week administration of semaglutide in HFD-induced NAFLD mice reduced body weight, glucose, insulin resistance, LFTs, serum lipids, inflammatory markers [TNF-α, interleukin (IL)-6, IL-1β], and oxidative stress markers [malonaldehyde (MDA)], thus improving hepatic steatosis, inflammation, mitochondria damage, and fibrosis. This evidence concerns the gene TNF and metabolic dysfunction-associated steatotic liver disease.